01:39 PM EDT, 08/30/2024 (MT Newswires) -- Catheter Precision ( VTAK ) said Friday that it priced an underwritten public offering of 347,277 common-stock units and 2.8 million pre-funded warrant units at $1.00 per unit and $0.9999 per unit, respectively, for gross proceeds of about $3.1 million.

Shares sank 56% as intraday trading volume catapulted to more than 2.22 million from a daily average of about 64,000.

NuCana ( NCNA ) said late Thursday that it is discontinuing phase 2 testing of the combination of its NUC-3373 drug candidate with leucovorin, irinotecan and bevacizumab for the potential colorectal cancer treatment.

Shares dropped 46% as intraday trading volume rose to over 272,000 from a daily average of about 111,000.

Elastic (ESTC) reported disappointing fiscal Q1 results behind a "poorly managed sales segmentation change" that led to fewer contracted commitments, Oppenheimer analysts said in a note.

Canaccord Genuity cut its price target for the stock to $110 from $125 while maintaining its buy rating.

Shares slumped 27% as intraday trading volume jumped to over 7.68 million from a daily average of roughly 1.14 million.

Price: 0.60, Change: -0.76, Percent Change: -55.88